A world-first clinical trial in Australia has found that Sailuotong (SLT), a Chinese herbal medicine compound, can significantly improve memory and executive functions in people with mild cognitive impairment (MCI).
Additionally, SLT was found to be well-tolerated, with researchers noting a low incidence of mild or moderate adverse events.
About SLT: SLT, which comes in capsules, is a Chinese herbal medicine containing standardized extracts of Panax ginseng, Ginkgo biloba and saffron (Crocus sativus L.). This unique preparation was co-developed and tested for over 15 years by researchers at Western Sydney University’s NICM Health Research Institute and Xiyuan Hospital at the China Academy of Chinese Medical Sciences in Beijing.
SLT has shown promise in addressing various aspects of MCI through its anti-inflammatory, antioxidant, antiapoptotic and cholinergic-enhancing properties. Previous studies also showed its potential cognitive benefits in vascular dementia and neurocognition in healthy adults.
What’s Next: The trial, which was in phase 2, included 78 participants aged 60 or older and diagnosed with MCI. The researchers hope to conduct another trial with a larger sample size and longer treatment period with different doses, ultimately to ascertain SLT’s long-term efficiency in managing cognitive impairment and preventing dementia.
Read the full article here